Merck Signs a ~$493M Deal with Cyprumed to Develop Oral Peptide Therapeutics
Shots:
- Cyprumed & Merck have entered into a non-exclusive license & option agreement to develop oral formulations of Merck’s peptides, leveraging Cyprumed’s innovative drug delivery tech
- As per the deal, Merck has secured non-exclusive global rights to Cyprumed’s oral peptide delivery platform for an undisclosed number of targets, with an option to exclusively license it for individual targets & will be responsible for research, development, manufacturing, & commercialization efforts
- Cyprumed will receive ~$493M in upfront, development, regulatory, & sales milestones contingent on product approvals, & is eligible to receive additional payments if Merck exercises its exclusive license option
Ref: Globenewswire | Image: Cyprumed & Merck
Related News:- Merck Presents P-III (3475A-D77) Trial Data of SC Keytruda for NSCLC at ELCC 2025
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
